移植后糖尿病危险因素研究进展  

Research progress in risk factors of post-transplantation diabetes mellitus

作　　者：董骏峰 薛强 滕飞 赵渊宇 殷浩 Dong Junfeng;Xue Qiang;Teng Fei;Zhao Yuanyu;Yin Hao(不详;Department of Organ Transplantation,the Second Affiliated Hospital of Naval Medical University(Shanghai Changzheng Hospital),Shanghai 200003,China)

机构地区：[1]海军军医大学第二附属医院(上海长征医院)器官移植科,上海200003 [2]海军军医大学第三附属医院(东方肝胆外科医院)神经外科

出　　处：《器官移植》2024年第1期145-150,共6页Organ Transplantation

基　　金：国家自然科学基金面上项目(82070798);上海市科学技术委员会生物医药创新项目(21S11905200);上海申康医院发展中心新兴前沿技术联合攻关项目(SHDC12021116);上海申康医院发展中心研究型医师创新转化能力培训项目(SHDC2022CRD030);上海长征医院转化医学孵育基金;上海长征医院科普人才扶持计划(CZQNKP-TYYX-QZ-2022-05)。

摘　　要：实体器官移植极大地延长了终末期疾病患者的生存时间,但器官移植受者术后需要长期服用免疫抑制药,会导致移植后糖尿病(PTDM)的发生风险增加,从而使感染、心血管疾病和死亡的风险升高。近年来,随着PTDM诊断标准的不断完善,临床医师对其认识越来越深入,与2型糖尿病相比,PTDM在病理生理特征和临床进展上存在着明显差异,需采用不同的治疗策略。及早识别器官移植受者的危险因素,早期诊断和干预对于改善受者的生活质量,延长移植物的存活时间以及降低受者病死率具有重要意义。因此,本文就PTDM的诊断、发生情况及危险因素做一综述,以期为临床医师早期识别并干预PTDM提供参考。Solid organ transplantation has significantly prolonged the survival of patients with end-stage diseases.However,long-term use of immunosuppressants will increase the risk of post-transplantation diabetes mellitus(PTDM)in the recipients,thereby elevating the risk of infection,cardiovascular disease and death.In recent years,with persistent improvement of diagnostic criteria of PTDM,clinicians have deepened the understanding of this disease.Compared with type 2 diabetes mellitus,PTDM significantly differs in pathophysiological characteristics and clinical progression.Hence,different treatment strategies should be adopted.Early identification of risk factors of organ transplant recipients,early diagnosis and intervention are of significance for improving the quality of life of recipients,prolonging the survival of grafts and reducing the fatality of recipients.Therefore,the diagnosis,incidence and risk factors of PTDM were reviewed in this article,aiming to provide reference for clinicians to deliver prompt diagnosis and intervention for PTDM.

关 键 词：器官移植 移植后糖尿病 钙调磷酸酶抑制剂 哺乳动物雷帕霉素靶蛋白抑制剂 糖皮质激素 巨细胞病毒 排斥反应 单核苷酸多态性 

分 类 号：R617[医药卫生—外科学] R587.1[医药卫生—临床医学]